Insider Sales Reported at Nurix Therapeutics and Chemring Group

Gwenn Hansen, an insider at Nurix Therapeutics (NASDAQ:NRIX), sold 4,111 shares for about $100,144 on August 4 under a pre‑arranged Rule 10b5‑1 plan, reducing her holding to 117,227 shares. The sale follows earlier transactions in late July and June, and comes as Nurix prepares for a Phase 1 trial milestone payment from Sanofi and a Phase 3 trial for bexobrutideg.

Michael Ord, an insider at Chemring Group plc (LON:CHG), sold 200,000 shares at an average price of GBX 612 on August 4, generating proceeds of £1.224 million. The transaction occurred as Chemring shares traded near their 52‑week high, with analysts maintaining a consensus buy rating.

Both companies disclosed the sales in filings with their respective securities regulators, and the insider transactions were executed under standard trading plans.